HomeCompareMSMKF vs ABBV

MSMKF vs ABBV: Dividend Comparison 2026

MSMKF yields 1.80% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MSMKF wins by $41.19M in total portfolio value· pulled ahead in Year 4
10 years
MSMKF
MSMKF
● Live price
1.80%
Share price
$18.17
Annual div
$0.33
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.29M
Annual income
$37,314,644.97
Full MSMKF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — MSMKF vs ABBV

📍 MSMKF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMSMKFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MSMKF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MSMKF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MSMKF
Annual income on $10K today (after 15% tax)
$153.21/yr
After 10yr DRIP, annual income (after tax)
$31,717,448.22/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, MSMKF beats the other by $31,695,581.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MSMKF + ABBV for your $10,000?

MSMKF: 50%ABBV: 50%
100% ABBV50/50100% MSMKF
Portfolio after 10yr
$20.70M
Annual income
$18,670,185.34/yr
Blended yield
90.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MSMKF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
6.3
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MSMKF buys
0
ABBV buys
0
No recent congressional trades found for MSMKF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMSMKFABBV
Forward yield1.80%3.12%
Annual dividend / share$0.33$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$41.29M$104.7K
Annual income after 10y$37,314,644.97$25,725.73
Total dividends collected$40.96M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: MSMKF vs ABBV ($10,000, DRIP)

YearMSMKF PortfolioMSMKF Income/yrABBV PortfolioABBV Income/yrGap
1$11,060$360.48$11,559$438.51$499.00ABBV
2$12,580$745.26$13,494$640.86$914.00ABBV
3$15,045$1,584.38$15,951$945.97$906.00ABBV
4← crossover$19,640$3,541.73$19,152$1,413.89+$488.00MSMKF
5$29,657$8,641.90$23,443$2,146.38+$6.2KMSMKF
6$56,124$24,391.45$29,391$3,321.96+$26.7KMSMKF
7$146,333$86,280.31$37,948$5,265.87+$108.4KMSMKF
8$577,063$420,486.33$50,795$8,596.74+$526.3KMSMKF
9$3,716,867$3,099,409.73$71,034$14,549.41+$3.65MMSMKF
10$41,291,692$37,314,644.97$104,715$25,725.73+$41.19MMSMKF

MSMKF vs ABBV: Complete Analysis 2026

MSMKFStock

MatsukiyoCocokara & Co. operates a chain of drug stores and pharmacies in Japan. As of June 30, 2020, it operated through a network of 1,726 stores in 47 prefectures in Japan. MatsukiyoCocokara & Co. was founded in 1932 and is based in Matsudo, Japan.

Full MSMKF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MSMKF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MSMKF vs SCHDMSMKF vs JEPIMSMKF vs OMSMKF vs KOMSMKF vs MAINMSMKF vs JNJMSMKF vs MRKMSMKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.